Sanofi-Aventis continues to move forward as a merged entity, naming Euro RSCG Life its second agency of record and unveiling its international public relations leadership.
The Havas-owned agency will handle the global advertising account
for thrombosis treatment Lovenox and for Lantus and Apidra diabetes therapies. The assignment includes advertising, medical education, public relations, DTC and interactive in
60 countries, including the 12 major markets worldwide. Financial terms of the agreement were not disclosed.
Back in January, Sanofi-Synthelabo appointed Publicis Groupe as its first worldwide communications agency of record. The three-year assignment, budgeted for 200 million euros (roughly $240 million) per year excluding media buying, included responsibility for both consumer and professional advertising.
Ron Pantello, Euro RSCG Life's chief executive, said in a statement
that the agency would put forward its expertise to craft a "unified, consistent" promotional message.
Sanofi-Aventis also unveiled theteam of executives to head up its
international communications arm. Leading PR efforts in the U.S. is
Charles Rouse, who has been named vice president, communications
USA. Rouse, who most recently served as vice president of North
American communications and corporate relations for Aventis, is currently selecting the U.S. PR team, which he said will be completed
within the next month or so. Rouse will report into the Sanofi-
Aventis global PR team led by Nicole Cranois, senior vice president
of communications. Jocelyne Coupat has been named vice president,
international relations of that team and Agnes Garcia-Gibot, vice president, internal communications and corporate image.
Additional global PR appointments include Michael Joly, vice president, product PR; William Bratton, deputy vice president; and
Jean-Marc Podvin, vice president, media relations.